H.C. Wainwright’s Swayampakula Ramakanth now bets on 54% in return potential for SESN stock on the heels of encouraging 3-month data in NMIBC.
RBC Capital’s Brian Abrahams believes that the exit of Celgene’s former BD chief is causing an unwarranted dip in the stock; here’s why.
RBC Capital’s Glen Novarro walks away upbeat on TRXC’s market opportunity following an encouraging non-deal roadshow with CFO Joe Slattery.
H.C. Wainwright’s Joseph Pantginis sees a “compelling” buying opportunity in PTN shares for biotech investors.
Oppenheimer’s Christopher Liu and Cantor’s William Tanner see potential in Synergy’s Trulance, even if its momentum is not full steam ahead just yet.
BTIG’s Tim Chiang is out with a positive research note, singing the praises of SGYP and 1Q earnings that put Trulance’s potential in the limelight.